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Cervical metastasis represent the most relevant prognostic 
factor in carcinomas of the mouth. Clinical and histological 
factors are associated with the development of cervical 
metastasis; however, research on molecular factors has 
been broadly carried out in recent years. Aim: The aim of 
this study is to analyze the association of the Cyclin D1 as a 
risk factor for the presence of cervical metastasis. Materials 
and methods: Cyclin D1 expression was measured and 
the association between such substance and metastasis was 
found in 45 patients with mouth cancer treated by the author 
of this paper. Cyclin D1 presence was checked through the 
stereological method. Clinical and histological characteristics 
have been analyzed and associated with metastasis. Results: 
Cyclin D1 expression was found in 15 patients but it was not 
associated with clinical and histological factors related to the 
presence of metastasis. Such conclusion indicates that Cyclin 
D1 is an independent protein. The most important predictive 
aspects related to metastasis development have been clinical 
staging and vascular embolization. Conslusions: Cyclin 
D1, although independent, is not associated with cervical 
metastasis, while staging and vascular embolization are. 
Keywords: cyclin d1, squamous cell carcinoma, mouth cancer 
metastases immunohistochemistry.
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INTRODUCTION
Epidermoid carcinoma corresponds to more than 
90% of malignant mouth tumors, and its survival is mo-
dified according to disease staging. When the disease is 
local, survival reaches 79%, loco-regional diseases yields 
42%; and 19% is the survival rate when there are distant 
metastasis1. Clinical, histological, and most recently biolo-
gical or molecular characteristics are considered prognostic 
factors, being predictive of cure and survival. The most 
important prognostic factor in mouth cancer is the pre-
sence of neck metastasis, and this makes the diagnosis of 
distant metastasis fundamental for the oncology treatment 
planning2,3.
Cervical metastasis identification is carried out 
through physical exam and complementary tests, which 
fail in the diagnosis of 20 to 35% of the clinically negative 
patients2,3. Such false negative rate is deemed high and 
justifies preventive neck treatment. When the primary 
tumor is treated exclusively, and there is hidden neck 
metastasis, there is a relevant reduction in patient survival. 
Patient selection for neck clearance is fundamentally ba-
sed on the tumor clinical characteristics, as to its size and 
location3. Histopathological characteristics, such as cellular 
differentiation level and tumor thickness also help in this 
selection; however, still keeps high failure rates. Tumor 
biological aspects are being researched in an attempt to 
identify which patients have a higher chance of developing 
neck metastasis3,4.
D1 cyclin is a protein coded by gene CCND1 located 
in chromosome 11q13. This protein acts on the cellular 
cycle, accelerating phase G1 and was described as an 
oncogene in 1991 by Motokura5, who observed that an 
increase in cyclin deregulates the cell cycle and contri-
butes to tumor genesis. D1 cyclin presence is shown by 
immunohistochemistry in head and neck cancer, and the 
higher its expression, the lower patient survival is, thus 
being considered a prognostic factor by many researchers 
in carcinomas of the esophagus, breast, uterine cervix, 
colon, rectum and melanomas5,6.
In the present investigation, we assessed D1 cyclin 
expression in a series of 45 patients with mouth epider-
moid carcinoma, and its association with neck metastasis. 
The goal of our study was to try and relate D1 cyclin 
expression as a risk factor for neck metastasis.
PATIENTS AND METHODS
1. Patients
We studied 45 patients with mouth epidermoid 
carcinomas who were operated by the author during the 
period of January 1991 and December of 2001. The patients 
suffered tumor surgical resection in its place of origin and 
neck lymphnode clearance. The neck lymphnodes surgery 
included patients who did not present clinical metastasis 
(N-), and those from patients who did present clinically 
diagnosed metastasis (N+).
D1 cyclin expression was carried out in histologic 
slides obtained from the primary tumor. We reviewed 
patients’ charts and collected pre-surgical clinical data, 
pathologic exam data from the surgical specimen and 
post-operative development.
Patients who presented one or more of the follo-
wing situations were taken off the study:
+ Surgery without curative intention.
+ Other concomitant neoplasias or history of prior 
tumors.
+ Neo-adjuvant therapy (chemo and radiothera-
py).
+ Patients whose chart data were incomplete.
+ Impossibility of defining clinical staging
2. Immunohistochemistry
We then obtained the paraffin blocks that had the 
primary tumors from the patients we were studying. From 
the main block of each tumor we obtained 4mm thick 
cross sections.
The sections were placed on 10% poly-L-lysine 
(Sigma, USA) pre-treated slides and taken to the oven at 
60oC for 24 hours.
Paraffin was taken off by means of 10 minute xy-
lene incubation for three times, followed by rehydration 
in ethanol sequence in decreasing concentrations, starting 
by absolute ethanol, 90%, 80% and 70% for 3 minutes in 
each dilution. Following that, the sections were washed 
three times in distilled water.
Antigenic sites recovery with trypsin digestion was 
carried out after heating at 37oC in a 0.1% trypsin solution 
with 0.1% calcium chloride in 7.8 pH. The slides were then 
incubated in this solution for 30 minutes at 37oC, and were 
then washed in distilled water.
High temperature antigen exposure was carried out 
by incubation in glass cradle, with a buffer containing 1mM 
of EDTA arranged in a 45o angle, in mean power for five 
minutes and fifty seconds, followed by eight minutes in 
low power (Panasonic, 1.500W microwave oven).
After recovering the antigenic sites we proceeded 
blocking endogenous peroxidase with H2O2 at 3%. After 
a 10 minute incubation, the slides were washed three 
times with distilled water and once with PBS pH 7.2. The 
sections were incubated for one hour with primary antigen 
anti-D1 cyclin (Dako, USA) at the concentration of 1:20, 
followed by two washings in PBS. After incubation with 
the primary antibody, the sections were incubated with 
the biotin-streptavidine system (Dako LSABâ2 System, 
USA) which consists of an anti-mouse/anti-rabbit antibody 
incubation biotinilated for 10 minutes, followed by a PBS 
washing and later incubation with streptavidine conjugated 
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with peroxidase. After 10 minutes of incubation, the slides 
were washed in PBS and a solution with diaminobenzidine 
(Dakoâ Liquid DAB Substrate Chromogen System, USA). 
After washing in distilled water, the slides were counter-
dyed with Harris hematoxylin for 15 seconds, washed in 
three water baths and dipped in an ammonia 37 mM so-
lution. After counter-dye, the slides were washed in three 
baths of warm water, followed by dehydration in growing 
ethanol concentrations (80%, 90% and pure, respectively) 
for three minutes in each dilution. After two treatments for 
five minutes in xylene, the sections were covered by thin 
slides assembled in Entellanâ (Merck, Germany).
The slides were analyzed under light microscopy 
aiming at assessing D1 cyclin expression.
D1 cyclin expression measure was carried out by 
means of a method called stereologic, which aim is to 
determine quantitative parameters from bi-dimensional 
sections of three-dimensional microscopic anatomical 
structures, by means of geometry and statistics7,8.
D1 cyclin expression was measured by the count 
of dyed nuclei divided by the area in mm2 and the value 
indicated by Qa 9.
Slide analysis was carried out under Olympus AX-
70 (Japan) light microscopy, coupled to a video camera. 
The images obtained were transferred to a computer and 
counts made with the help of the Image Pro Plus version 
4.1 software (Media Cybernetics, USA). On an image taken 
from a 20x lens we applied a grit that divided it in nine 
equal fields, according to Figure 1.
From each slide we obtained five values and cal-
culated the average of five Qa obtained.
3. Statistical analysis
The quantitative variables were described by avera-
ge and standard deviation, and percentages were used for 
the qualitative variables. The group’s quantitative variables 
were compared by means of the Student t test, and for the 
qualitative variables we used the chi-squared test. Associa-
tion measures such as the odds ratio and the relative risk 
with its respective confidence intervals were completely 
performed. In order to adjust the association between 
cyclin and metastasis in front of so diverse potential risk 
factors, we used the multivariate logistical regression.
Survival curves were calculated using the Kaplan-
Meyer’s method. Death that did not occur because of the 
primary tumor or from its metastasis were not considered 
treatment failures, but rather censored observations. The 
differences between the survival curves were compared 
by the log rank test. In order to simultaneously adjust the 
effects of many factors considered and their relation with 
death, we used Cox regression. The P values below 0.05 
were considered statistically significant, and the multiva-
riable models considered P values below 0.1.
For the statistical analysis, data was processed and 
analyzed with the help of the SPSS (Statistical Package 
for Social Science) software for Windows and Excel 97, 
version 11.1.
4. Ethics
The study is in compliance with items III.3.i and 
III.3.t from the Research Regulatory Guidelines and Stan-
dards involving Human Beings (Resolution CNS 196/96), 
as well as Guideline 12 from the International Ethics Gui-
delines for Biomedical Research Involving Human Beings 
(CIOMS 1993).
The principles present in the Helsinki Declaration 
were abided (WORLD MEDICAL ASSOCIATION, 1996), 
keep confidential the patients’ identities, whose data were 
identified only by the record number in the project. 
The project was submitted and approved by the 
Research Ethics Committee of the Pontifícia Universidade 
Católica do Rio Grande do Sul (Protocol number 298/01 
- CEP).
RESULTS
D1 cyclin clinical and histologic characteristics of 
the 45 patients studied may be seen on Table 1. 
D1 cyclin was positive in 15 (33.3%) cases and ne-
gative in the remainder 30 (66.7%). The average of labeled 
nuclei (Qa) varied between 0.15 and 1.24 in the positive 
cases. The protein presence in the cell nucleus may be 
seen in Figure 2. 
The protein expression in the cell cytoplasm was 
also observed in three patients. 
The associations and correlations between patients 
with metastasis (pN+) and those without it (pN-) were 
Figure 1. Diagram showing the fields observed in the slide - * The 
dark area indicated where D1 cyclin labeled nuclei were counted.
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Table 1. Comparison between metastatic and non-metastatic groups as to the following variables: demographics, habits and clinical traits, 
histology and tumor molecular characteristics.
Variable
With metastasis
(n=23)
Without metastasis
(n=22)
OR IC95% P
Age, years 59,0±11,4 57,0±11,0 1,02 0,96 a 1,07 0,543
Gender, # (%)
Males 22 (95,7) 18 (81,8) 4,9 0,5 a 47,7 0,187
female 1 (4,3) 4 (18,2) -
Smoking, nº (%)
yes 18 (78,3) 18 (81,8) 0,8 0,2 a 3,5 0,999
no 5 (21,7) 4 (18,2) -
Alcohol intake, #º (%)
yes 13 (56,5) 12 (54,5) 0,9 0,3 a 3,0 0,999
no 10 (43,5) 10 (45,5) -
Tongue, # (%)
Involved 12 (52,2) 14 (63,6) 0,6 0,2 a 2,1 0,634
Not involved(a) 11 (47,8) 8 (36,4) -
Classification T (tumor), nº (%)
T1 and T2(a) 12 (52,2) 16 (72,7) -
T3 and T4 11 (47,8) 6 (27,3) 2,4 0,7 a 8,5 0,265
Clinical staging, # (%)
I e II(a) 4 (17,4) 13 (59,1) -
III e IV 19 (82,6) 9 (40,9) 6,8 1,7 a 27,1 0,010
Degree of differentiation, # (%)
G1 0 (0,0) 1 (4,5) 0,2(b) (0,0 a 16,7) 0,462
G2 16 (69,6) 16 (72,7) 0,7 (0,2 a 3,3) 0,878
G3(a) 7 (30,4) 5 (22,7) -
Embolization, # (%)
Present 14 (60,9) 4 (18,2) 7,0 1,8 a 27,5 0,009
Absent(a) 9 (39,1) 18 (81,8) -
Nerve involvement, nº (%)
Present 14 (60,9) 11 (50,0) 1,6 0,5 a 5,1 0,665
Absent(a) 9 (39,1) 11 (50,0) -
Cyclin, nº (%)
[+] 9 (39,1) 6 (27,3) 1,7 0,5 a 6,0 0,598
[-](a) 14 (60,9) 16 (72,7) -
Data presented as average ± standard deviation and frequency (percentage). OR: odds ratio; CI95%: Confidence Interval of 95%. (a) Referen-
ce category in the calculation of odds ratio; (b) Odds ratio adjusted by Agresti’s method.
carried out base don clinical and histological traits, habits, 
demographics and D1 cyclin, are depicted on Table 1. The 
multivariate analysis used to asses the risk of D1 cyclin 
association with other potential risk factors was carried 
out and is depicted on Table 2. 
Survival was assessed based on D1 cyclin expression 
and the presence of metastasis in months, by means of a 
survival curve of which outcome considered was death 
due to mouth cancer, which occurred in seven situations. 
Results may be seen in Figures 3 and 4. 
D1 cyclin effect was adjusted based on potential risk 
factors for survival assessment and is depicted on Table 3. 
D1 cyclin effect on survival adjusted by the multivariable 
Cox regression model containing clinical staging, tongue 
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Figure 2. D1 cyclin expression - D1 cyclin expression dyed in Brown 
in the nucleus of neoplastic cells.
Table 2. Multivariable logistic regression model which adjusts the 
cyclin effect [+] when facing many potential risk factors for its asso-
ciation with metastasis.
Variable OR CI90% P
Cyclin [+] 2.7 0.6 a 11.6 0.267
Clinical staging III and IV  16.4 2.8 a 95.5 0.009
Tongue involvement 0.2  0.1 a 0.9 0.068
Vascular embolization 4.3 1.1 a 17.5 0.084
Cellular differentiation G3 8.1 1.2 a 53.4 0.069
Nerve involvement 0.5  0.1 a 2.1 0.460
OR: odds ratio; CI90%: Confidence Interval of 90%.
Figure 3. Metastasis and survival - Kaplan-Meier’s chart showing death 
occurrence stratified by metastasis presence or absence. 
Figure 4. D1 cyclin and survival - Kaplan-Meier’s chart showing 
death occurrence stratified by positive ([+]) and negative ([-]) cyclin 
groups.
Table 3. Multivariable Cox regression model which adjusts the cyclin 
effect [+] when facing many potential risk factors for its association 
with death.
Variable RR CI90% P
Cyclin [+] 0.8 0.2 to 3.5 0.846
Clinical staging III and IV 4.9 0.6 to 37.9 0.198
Tongue involvement 1.0 0.2 to 5.7 0.964
Vascular embolization 1.6 0.3 to 7.2 0.625
G3 Cell differentiation G3 3.6 0.6 to 20.9 0.226
Nerve involvement 0.4 0.1 to 2.4 0.409
OR: odds ratio; CI90%: Confidence Interval of 90%.
Figure 5. D1 cyclin and survival - Multivaried analysis - Survival chart 
comparing positive ([+]) and negative ([-]) cyclin groups with adjusted 
effects in multivariable Cox’s regression model, bearing clinical staging, 
tongue involvement, cell differentiation, vascular embolization and 
nerve invasion factors. 
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involvement, cell differentiation, vascular embolization 
and nerve involvement were studied and are depicted 
on Figure 5.
DISCUSSION
D1 cyclin was expressed in 15 (33.3%) patients 
from the sample, which is in agreement with published 
results that vary between 30 and 40%10-12, although by a 
distinct methodology of immunohistochemistry reading. 
The literature on D1 cyclin and cancer assesses the pre-
sence of cyclin by counting the nuclei labeled by a group 
of neoplastic cells, which usually vary between 500 and 
1000 cells, in percentages. By means of such method, 
the investigator needs to count a total of neoplastic cells, 
regardless whether they are marked or not, and after that, 
recounting the cells that express the protein, and calculate 
the percentage. Besides being a labor-intensive method, it 
bears a higher risk of distortions in counting. The choice of 
cutting point that separates the positive from the negative 
D1 cyclin expression is arbitrary. Han et al.13, consider it 
positive when there is more than 5% of labeled nuclei. 
Ravi et al.14, Itami et al.11 and 
Capaccio et al.12, consider the D1 cyclin expression 
only significant when present in over 10% of the tumoral 
cells. El-Naggar et al.15 consider values above 50% as an 
overexpression of this protein. Mineta et al.16 consider 
values between 0-50% being of low expression, and those 
above 50% as being of high expression. Schoelch et al.10 
use the negative score when there is no expression, + for 
up to 33% expression, ++ between 33 and 66% and +++ 
above 66% of protein expression in tumor cells.
The stereological method used in this investigation 
assess the protein expression in the nuclei by tumor area, 
is more reliable8,9. The protein expression in the cell cyto-
plasm was also observed as described in other studies17.
D1 cyclin may be expressed in different intensity 
levels. The term “high expression” is defined by the la-
beling of more than 50% of the neoplastic cells10. In the 
present study, Qa results obtained for the 15 positive pa-
tients varied from 0.15 to 1.27, and the differences of the 
values found were not significant. It was not possible to 
establish the cyclin expression in low and high expression 
because of patient sample size; however, the quantitative 
analysis of Qa values was carried out.
D1 cyclin expression in the 15 positive patients 
was not constant in the whole tumor surface area. In all 
the cases, protein expression analysis was carried out 
in the region of greatest labeling in the slide, showing 
tumor areas that did not express the protein. This lack of 
labeling constancy may be justified by the fact that about 
20% of the neoplastic cells are under mitosis18. Conside-
ring this asymmetrical expression distribution, one could 
question the studies in which the researchers used biopsy 
specimens, as reported by Michalides et al.19, where D1 
cyclin expression false negatives were observed in biopsy 
material when compared to the surgical specimen; none-
theless, further studies are required in order to measure 
which is the true sensibility of D1 cyclin expression in 
biopsy material compared to a surgical specimen. This 
is relevant, since false negatives occurring in the biopsy 
material would compromise the clinical application of 
such marker when a treatment decision is to be made, for 
example, whether or not to indicate neck clearance in a 
patient clinically classified as N0.
As to gender, smoking and alcohol intake, there was 
no relation with the presence of neck metastasis and the 
invasion of lymphnode capsule, which confirms that they 
do not represent risk factor for neck metastasis16.
Age was also not related to the presence of neck 
metastasis and lymphnode capsule invasion, although very 
young and very old patients develop tumors with more 
aggressive behavior20.
As to location, there was also no association with 
the presence of metastasis. The 14 T1 and T2 patients 
with tongue epidermoid carcinomas presented metastasis 
in six cases, while the remaining 14 T1 and T2 patients 
classified as having cancer in other parts of the mouth 
presented metastasis in six cases. Location is not impor-
tant when the tumor is large, as is the case with T3 and 
T4 tumors that already bear high metastasis development 
risk individually.
Tumor location in the mouth was associated to lym-
phnode capsule invasion. The tumors that involved more 
than one location in the mouth had greater involvement 
of the lymphnode capsule; with a p value of 0.049.
Twelve of the 28 T1 and T2 patients presented 
histologic metastasis (42.8%), a value close to expected, 
which is of 20 to 40%. As to the 17 T3 and T4 patients, 11 
had metastasis (64.7%) in agreement with the literature21. 
There was no statistical relation between tumor size and 
metastasis (P = 0.265). We also did not find significant 
association between tumor size and metastatic lymphnode 
capsule invasion (P = 0.089).
Regarding the classification N, histology showed that 
of the 25 negative cases, eight (32%) were false negatives 
and 17 (68%) were true negatives. As to the 20 N+ patients, 
histology revealed five (25%) false positive patients, and 
in 15 (75%) neck metastasis was confirmed. The P value 
found was of 0.001 for neck metastasis and 0.047 for cap-
sule invasion. The number of false positives was of 25%, 
corresponding to what has been described in the literature, 
which is 20%, while the rate of false negatives was of 32%, 
while the value reported in the literature lays between 20 
and 35%22,23. Metastasis patients’ stratification was not stu-
died in the present investigation, due to the small number 
of patients allocated in each subdivision N. 
Clinical staging was significant in the association 
with neck metastasis. When the staging of a mouth can-
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cer patient is defined, it is considered tumor size and the 
clinical presence of metastasis by neck palpation. Since 
patients classified as positive N are in stages III and IV, 
the value found is not surprising and is directly associated 
with the incidence of false positives and false negatives on 
neck palpation, which in the present study was of 25% and 
32% respectively. Neck palpation and the T classification 
alone were not significant, and this by itself justifies the 
use of a staging process.
The degree of cell differentiation was not associated 
to the presence of neck metastasis or with lymphnode 
capsule invasion. The presence of only one patient with 
well differentiated epidermoid cancer made it impossible 
to observe the relationship between the degree of diffe-
rentiation and the risk of metastasis development. 
Nerve sheath invasion was not associated to the pre-
sence of neck metastasis, nor to the invasion of lymphnode 
capsules. Nerve sheath invasion happened in 14 (60.9%) 
of the 23 metastatic patients; however without statistical 
meaning. There was also no association between nerve 
sheath invasion and lymphnode capsule invasion.
Vascular embolization was predictive as far as 
metastasis presence is concerned. Woolgar24 found 78% 
of vascular invasion in N positive patients and 70% nerve 
sheath invasion in another sample also of 45 patients with 
mouth epidermoid carcinoma. In the present study we 
found 60.9% for both situations; however with different 
meaning when we observe the results of the proper sta-
tistical significance tests, and this shows the relevance of 
data analysis tests, thus avoiding misinterpretations. 
D1 cyclin expression is not associated to metastasis. 
D1 cyclin quantified by Qa value also did not change the 
results. The lack of studies published in the literature using 
the stereological method makes it impossible to compare 
quantitative results. Cyclin was also not associated to me-
tastatic lymphnode capsule invasion. 
In the literature, the association between D1 
cyclin expression and the presence of neck metastasis 
is ambiguous. The results of the present investigation 
agree with those presented by Han et al.13, Michalides et 
al.19,25 and Bellacosa et al.26. However, the papers from 
Frachiolla27, Itami11, Masuda28, Tapia et al.29, Capaccio et 
al.30 and Mineta et al.16 showed that D1 cyclin is indeed 
associated with the presence of neck metastasis. Results 
are contradictory and the reasons may be the following: 
D1 cyclin expression differ in the different organs of the 
body; the very condition of the surgical specimen such 
block tumor and formaldehyde time until it is fixed; cutting 
point used to define what is protein overexpression and 
a standard reading methodology avoiding interpretation 
subjectiveness.
D1 cyclin multivaried analysis with the most relevant 
prognostic factors did not change the results, showing 
that D1 cyclin expression does not depend on the other 
factors studied, agreeing with the findings from Capaccio 
et al.30 and Mineta et al.16.
The survival curve of the 45 patients in the sam-
ple shows that D1 cyclin positive patients have a lower 
tendency to survive when compared to negative patients, 
although the statistical significance was weak. 
Survival analysis concerning metastasis reveals that 
neck metastasis patients present lower survival rates, and 
confirms the meaning of neck metastasis as a prognostic 
factor associated with mouth cancer. 3,31-33.
Multivaried analysis shows that D cyclin and neck 
metastasis are independent factors as to their relation with 
survival, agreeing with the results from Han et al.13. These 
authors did not find associations between D1 cyclin and 
the presence of metastasis in gastric cancer, and found 
an association with patient survival. Michalides et al.19,25 
studied head and neck carcinomas and Bellacosa et al.26 
studied patients with larynx cancer and also did not re-
port correspondence between metastasis and D1 cyclin 
expression; nonetheless, they did find relations with pa-
tient survival. 
In the present investigation, neck metastasis was 
significant in survival reduction, while D1 cyclin did not 
show the same statistical significance, only showing a 
trend that patients with higher cyclin expression had worse 
survival rates.
CONCLUSIONS
The present investigation leads us to conclude 
that:
a. D1 cyclin expression seems to be independent 
from mouth epidermoid carcinoma.
b. It is very likely that D1 cyclin is not associated 
with the presence of neck metastasis.
c. Vascular embolization and clinical staging were 
the most significant factors as neck metastasis predictors 
in the cases hereby studied. 
d. Neck metastasis was significant in the survival 
of our patients in this study, while the same can not be 
said about D1 cyclin.
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